Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571389 · ClinicalTrials.gov registry record
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
A clinical trial of Solid Tumor, Adult and Healthy Donors, sponsored by BioCytics.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT00571389 is a study of Solid Tumor, Adult and Healthy Donors that is actively recruiting participants, run by BioCytics. The registered enrollment target is 1,500 participants, above the 170-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (782% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00571389, a study of Solid Tumor, Adult and Healthy Donors, is actively recruiting participants, sponsored by BioCytics.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.
Conditions Studied
Study Locations (1)
North Carolina
- Carolina BioOncology Institute - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2007-11 |
| Est. Completion | 2030-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571389
The ClinicalTrials.gov registry entry for NCT00571389 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 170-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (782% higher). The listed sponsor is BioCytics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 0 interventions.
NCT00571389 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00571389 about?
NCT00571389 is a clinical study titled "A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.". Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral bl...
What is the current status of trial NCT00571389?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2007-11. Estimated completion is 2030-02.
What conditions does trial NCT00571389 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, Healthy Donors, COVID-19 Donors.
Who is sponsoring clinical trial NCT00571389?
This trial is sponsored by BioCytics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00571389 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.